R&D JP Morgan Week 2025 - Day 3 pharmaphorum's JPM Week live blog finishes strong with panels on AI, funding, and a conference wrap-up.
R&D Pharma trends and predictions for 2025: An incoming CEO’s pe... Over the past two decades, I’ve observed significant shifts in the life sciences, pharmaceutical, and CDMO landscape.
R&D Delivery: The key to navigating pharmacy deserts in 2025 Pharmacy closures are accelerating fast.
R&D Life Sciences Industry Report 2025 - GLP-1S: Applicability i... The pharmaceutical landscape in 2024 was undeniably shaped by the remarkable rise of GLP-1 receptor agonists.
R&D JP Morgan Week 2025 - Day 2 On day 2 of pharmaphorum's JPM Week blog, we'll hear from leaders from the President of Novartis, a stacked industry panel on AI, and Dr Jill Biden.
R&D The intricacies of effectively transitioning active clinical... European Union lawmakers designed EU Clinical Trial Regulation 536/2014 to heighten interest within the healthcare industry for planning and conducting clinical trials in the
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
